Conference LibraryGated
Claim · EsoBiotec ENaBL lentiviral platform validated via $1B AstraZeneca acquisition
EsoBiotec ENaBL (Engineered NanoBody Lentiviral) 第三代 immune-shielded lentiviral vector 平台 · 是首个被 big pharma 完全收购的 in vivo CAR-T delivery platform (AstraZeneca $1B in 2025-03) · 为 in vivo lentiviral delivery 提供 platform-level validation anchor。SunVax 与潜在客户讨论 LNP delivery platform…
- Type
- claim
- Domain
- car-t
- Grade
- conference
- License
- LIGHT_HOPE_proprietary
- Provenance
- m622_intel_seed_2026-05-16
- evidence_grade
- A
- category
- platform_validation_claim
- status
- verified
- instance_tag
- sunvax-antibody-2025
- claim_statement
- EsoBiotec ENaBL (Engineered NanoBody Lentiviral) 第三代 immune-shielded lentiviral vector 平台 · 是首个被 big pharma 完全收购的 in vivo CAR-T delivery platform (AstraZeneca $1B in 2025-03) · 为 in vivo lentiviral delivery 提供 platform-level validation anchor。SunVax 与潜在客户讨论 LNP delivery platform
- claim_evidence_grade
- A
- supporting_papers
- m622-b5-paper-esobiotec-pr-2024-001,m622-b5-paper-labiotech-azn-acquisition-001
Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.